Lupin Limited believes it has “the potential to offer significant cost savings” for the UK’s National Health Service after launching the first generic version of Chiesi’s Fostair (beclometasone/formoterol) 100mcg/6mcg dose pressurized metered dose inhaler.
Lupin Delivers On Generic Fostair With UK Luforbec Launch
UK’s NHS Spends Around $250m Per Year On Asthma And COPD Treatment
Having previously seen patent litigation with originator Chiesi dismissed, Lupin has realized plans to launch the first UK generic version of Fostair (beclometasone/formoterol), with the potential for significant cost savings for the UK’s National Health Service.
